Left atrial appendage closure in patients with prior intracranial bleeding, safety, efficacy, and timing

D Gonzalez-Calle1, L Nombela-Franco2, H Gutierrez-Garcia3

  • 1Hospital Universitario de Salamanca, CIBERCV, IBSAL, Spain.

Neurologia
|September 3, 2025
PubMed

Insights

Left atrial appendage occlusion (LAAO) is a safe and effective alternative to oral anticoagulation for patients with atrial fibrillation and prior intracranial hemorrhage. Early versus late LAAO showed similar safety and efficacy outcomes.

Area of Science:

  • Cardiology
  • Neurology
  • Medical Devices

Background:

  • Oral anticoagulation (OAC) increases intracranial hemorrhage (ICH) risk in atrial fibrillation (AF) patients.
  • Left atrial appendage occlusion (LAAO) offers an alternative to OAC, but data in prior ICH patients is limited.
  • The optimal timing for LAAO in patients with prior ICH remains controversial, with limited long-term outcome data.

Purpose of the Study:

  • To assess the safety and efficacy of LAAO in non-valvular AF patients with a history of ICH.
  • To determine the appropriate timing for performing LAAO after ICH.
  • To evaluate long-term outcomes following LAAO in this high-risk patient population.

Main Methods:

  • A multicenter retrospective registry of 128 patients with AF and prior ICH undergoing LAAO.
  • Patients were stratified into early occlusion (before 90 days post-ICH, n=31) and late occlusion (after 90 days post-ICH, n=97) groups.
  • Comparison of procedural success, complications, and long-term clinical outcomes (ischemic and bleeding events, mortality).

Main Results:

  • High procedural success rate (97%) with low complication rates (3.15%).
  • Significant reduction in expected ischemic and bleeding rates post-LAAO.
  • No significant differences in baseline characteristics, procedural outcomes, or long-term mortality, ischemic events, or hemorrhage between early and late occlusion groups.

Conclusions:

  • LAAO is a safe and effective treatment for reducing ischemic stroke risk in AF patients with prior ICH.
  • Early LAAO (before 90 days) demonstrated comparable safety and efficacy to late LAAO.
  • Further research is warranted to support early LAAO to mitigate risks associated with oral anticoagulation withdrawal.
Abstract